Literature DB >> 2524389

Pharmacokinetics of amlodipine in renal impairment.

G D Doyle1, J Donohue, M Carmody, M Laher, H Greb, M Volz.   

Abstract

Amlodipine was administered as 14 single 5-mg oral daily doses to 27 male subjects with renal function ranging from normal to haemodialysis-dependent. Blood specimens were obtained for measurement of plasma amlodipine concentrations for 24 h following the first dose, for 168 h following the final dose and during daily administration of amlodipine. Amlodipine was well tolerated. Renal impairment had little effect on the pharmacokinetics of amlodipine. The elimination half-life was of the order of 50 h, similar to previously reported values and did not vary with renal function. Steady-state pre-dose concentrations were observed after the ninth dose. Accumulation of amlodipine was not significantly different from that expected on theoretical grounds and did not significantly change with renal function. These results suggest that once daily administration of amlodipine is suitable for all degrees of renal function and that dosage adjustment is not necessary in renal impairment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524389     DOI: 10.1007/bf00609197

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Once daily amlodipine in the treatment of mild to moderate hypertension.

Authors:  J Webster; O J Robb; T A Jeffers; A K Scott; J C Petrie; H M Towler
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

2.  Metabolism and kinetics of amlodipine in man.

Authors:  A P Beresford; D McGibney; M J Humphrey; P V Macrae; D A Stopher
Journal:  Xenobiotica       Date:  1988-02       Impact factor: 1.908

3.  Analysis of amlodipine in human plasma by gas chromatography.

Authors:  A P Beresford; P V Macrae; D A Stopher; B A Wood
Journal:  J Chromatogr       Date:  1987-09-04

4.  The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily.

Authors:  J K Faulkner; D McGibney; L F Chasseaud; J L Perry; I W Taylor
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

  4 in total
  2 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Pharmacokinetic profile of nifedipine GITS in hypertensive patients with chronic renal impairment.

Authors:  R Schneider; D Stolero; L Griffel; R Kobelt; E Brendel; A Iaina
Journal:  Drugs       Date:  1994       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.